Kenvue Inc. $KVUE Position Boosted by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC

Key Points

• UBS Asset Management increased its holdings in Kenvue Inc. by 15.2% in Q1, owning roughly 0.74% of the company, valued at $339 million.
• Kenvue reported an earnings per share (EPS) of $0.29 for the last quarter, surpassing analysts' expectations, though revenue fell 4% year-over-year.
• The company recently declared a quarterly dividend of $0.2075, reflecting a 4.5% dividend yield despite a payout ratio of over 112%.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 15.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,143,451 shares of the company's stock after purchasing an additional 1,862,258 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 0.74% of Kenvue worth $339,160,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in KVUE. Starboard Value LP bought a new position in shares of Kenvue during the 4th quarter valued at about $467,864,000. Vanguard Group Inc. boosted its position in shares of Kenvue by 4.9% during the 1st quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company's stock valued at $5,494,882,000 after purchasing an additional 10,600,682 shares in the last quarter. Third Point LLC bought a new position in shares of Kenvue during the 1st quarter valued at about $213,422,000. Maverick Capital Ltd. bought a new position in shares of Kenvue during the 1st quarter valued at about $203,036,000. Finally, Nuveen LLC bought a new position in shares of Kenvue during the 1st quarter valued at about $187,123,000. Institutional investors own 97.64% of the company's stock.

Kenvue Price Performance

NYSE KVUE opened at $18.46 on Thursday. The company has a 50 day simple moving average of $21.23 and a 200-day simple moving average of $22.30. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68. The firm has a market capitalization of $35.42 billion, a price-to-earnings ratio of 24.94, a price-to-earnings-growth ratio of 2.71 and a beta of 0.83. Kenvue Inc. has a 52-week low of $17.15 and a 52-week high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.28 by $0.01. The business had revenue of $3.84 billion during the quarter, compared to analyst estimates of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The firm's revenue was down 4.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.32 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were given a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.5%. This is a positive change from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Wednesday, August 13th. Kenvue's payout ratio is currently 112.16%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on KVUE. JPMorgan Chase & Co. reduced their price objective on shares of Kenvue from $27.00 to $26.00 and set an "overweight" rating for the company in a research report on Friday, July 25th. Bank of America reduced their price objective on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a research note on Tuesday, July 15th. Citigroup reduced their price objective on shares of Kenvue from $24.50 to $22.00 and set a "neutral" rating for the company in a research note on Tuesday, July 15th. Canaccord Genuity Group reduced their price objective on shares of Kenvue from $29.00 to $26.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Finally, Barclays reduced their price objective on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research note on Tuesday, July 15th. Five research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $24.21.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.